Related Experiment Video
Updated: Jan 11, 2026
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Melatonin for sleep and cognitive outcomes in older adults with cognitive impairment: a meta-analysis of randomised
Nosipho Treasure Mdluli1, Kondwani Joseph Banda2,3, Yun-Chen Chang4,5
1Ph.D. Program for Aging, College of Medicine, China Medical University, Taichung 404, Taiwan.
Objectives:
To quantify the effects of melatonin on total sleep time and global cognition, and to examine secondary outcomes (sleep efficiency, circadian markers, neuropsychiatric symptoms, depression, activities of daily living) in older adults with cognitive impairment.
Design:
Systematic review and meta-analysis of randomised controlled trials (PROSPERO CRD42024539227).
Data Sources:
PubMed, PsycINFO (via EBSCOhost), CINAHL Plus, Cochrane Library, Web of Science, to October 2024.
Eligibility Criteria:
Randomised controlled trials (RCTs) comparing melatonin versus placebo in adults ≥65 years with mild cognitive impairment or dementia.
Data Extraction And Synthesis:
Two reviewers extracted data; risk of bias was assessed by RoB 2. Random-effects models estimated Hedges' g and mean differences (MD), with Benjamini-Hochberg false discovery rate (FDR) correction for multiple outcomes. Heterogeneity assessed via I2; publication bias via Egger's test.
Results:
Ten RCTs (n = 516) were included. Melatonin increased total sleep time by MD +12.4 min (95% CI 8.1-16.7; P < .001; I2 = 72%; g = 0.42) and improved Mini-Mental State Examination scores by MD +1.8 points (95% CI 0.9-2.7; P = .002; I2 = 65%; g = 0.47). Neuropsychiatric symptoms decreased (g = -0.23; 95% CI -0.44 to -0.03; P = .02). Effects on sleep efficiency, circadian markers, depression and activities of daily living were small and nonsignificant.
Conclusions:
Melatonin yields modest improvements in sleep duration and cognition that approach clinically important thresholds but fall short of definitive efficacy. Larger, rigorously designed RCTs with harmonised outcomes and pre-specified primary endpoints are needed to confirm these findings.
More Related Videos
Related Concept Videos
01:19Management of Insomnia
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:30Cognitive Development During Adulthood
01:11Understanding Sleep
The circadian rhythm, a nearly 24-hour cycle, is deeply influenced by environmental light cues. Light exposure directly affects the hypothalamus, which in turn regulates...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age